1. At a Glance – Blinkit Speed, Buyback Swagger, and a Balance Sheet on Diet

If 2021 Nureca was that overexcited lockdown fitness influencer who bought dumbbells and never used them, then 2025–26 Nureca is the same guy quietly hitting the gym at 6 a.m., losing fat, and posting fewer selfies. Market cap sits around ₹298 crore, current price near ₹312, and the stock has delivered a respectable ~21% return over six months—no moonshot, but definitely not a coma patient either. The latest quarter (Q3 FY26) is where the plot thickens: revenue clocked ₹39.6 crore, up nearly 50% YoY, while PAT jumped a dramatic 233% to ₹3.73 crore. EPS came in at ₹3.91 for the quarter, which suddenly makes people sit up and stop scrolling.

The company remains almost debt-free (debt ~₹5.39 crore, debt-to-equity ~0.03), which in today’s leveraged corporate India is like spotting a unicorn calmly sipping coconut water. ROCE and ROE are still negative on a trailing basis, reminding us that past sins haven’t been fully washed away, but operating margins have turned positive again. Add to that a completed ₹19.14 crore buyback at ₹330 per share, quick-commerce penetration under 30 minutes, and a manufacturing plant approval in Punjab, and you have a company that’s trying very hard to rewrite its own biography. The question is simple: is this a genuine turnaround, or just a well-edited Instagram reel?

2. Introduction – The Rise, Fall, and “Abhi Toh Trailer Hai” Comeback

Nureca Ltd was incorporated in 2016, long before everyone suddenly discovered pulse oximeters and nebulizers during COVID. During the pandemic, Nureca—through brands like Dr Trust and Dr Physio—became a household name faster than dalgona coffee trends. Sales exploded, margins swelled, and investors behaved like they had found the next consumer-tech unicorn hiding in Ludhiana.

Then reality arrived. Post-pandemic demand normalized, inventory piled up, working capital days ballooned, margins collapsed, and profitability vanished faster than New Year gym resolutions. From FY22 to FY24, revenue shrank, ROCE went negative, and the market punished the stock mercilessly. This is the phase where long-term charts start looking like a ski slope and Twitter experts go mysteriously silent.

Fast forward to FY25 and Q3 FY26, and something interesting is happening. Revenue is growing again, operating profits have returned, and PAT is no longer allergic to positive numbers. The company has refocused on faster-moving SKUs, improved channel mix, leaned into quick commerce, and is investing in local manufacturing to reduce import dependence. This is not a fairy tale turnaround yet—but it’s definitely not a horror movie anymore. For investors, Nureca today feels like a probation period employee who messed up badly but is suddenly showing up on time with results.

3. Business Model – WTF Do They Even Do?

At its core, Nureca is a digitally-first consumer healthcare company. Translation: they sell medical and wellness products directly to you while cutting out as many middlemen as possible, and they love the internet more than mall kiosks.

The company operates across multiple product buckets. Chronic disease management includes BP monitors, nebulizers, glucometers, thermometers, and pulse oximeters—basically the gadgets your parents suddenly learned to use during COVID and never stopped checking. Lifestyle and fitness products cover humidifiers, steamers, personal scales, massagers, yoga equipment, fitness trackers, and dental care. Ortho care is handled under the Dr Physio brand with orthopedic cushions, memory foam pillows, pain management devices, and rehab equipment. There’s also a mother & baby segment via Trumom, plus a nutrition line of supplements in capsules, tablets, and liquids.

What makes Nureca interesting (and slightly techy) is its connected devices ecosystem. Products like ECG machines, smart BP monitors, glucometers, and weighing scales connect to the Dr Trust 360 App, creating a small but growing digital health ecosystem. This isn’t Apple Health-level sophistication, but for an Indian mid-cap, it’s not jugaad either.

Sales are overwhelmingly online—around 93% in Q1 FY26—via D2C websites, marketplaces, and increasingly quick-commerce platforms like Blinkit, Swiggy Instamart, and Zepto. Offline distribution exists (192+ distributors, ~22,000 retail touchpoints), but online is clearly the kingpin. Nureca is essentially betting that India’s future healthcare shopping looks more like ordering groceries at midnight than visiting a medical store at 9 a.m.

4. Financials Overview – The Numbers That Finally Stopped Crying

Result Type Lock: The latest announced results are Quarterly Results. EPS is therefore annualised by multiplying the latest quarterly EPS by four.

Q3 FY26 Performance Snapshot (₹ crore)

Annualised EPS (Quarterly): ₹3.91 × 4 = ₹15.64

The headline here is not just growth—it’s consistency. This is the second consecutive profitable quarter, with operating margins firmly in positive territory (~8.2%). Revenue growth is strong both YoY and QoQ, indicating that demand recovery isn’t a one-off festive miracle.

However, before anyone starts lighting diyas, remember that a chunk of historical profits included other income, and working capital remains stretched. Still, compared to the losses of FY23–FY24, this quarter feels like a proper comeback episode rather than a blooper reel.

5. Valuation Discussion – Not Cheap, Not Crazy, Just…